Novavax (NVAX) reported Q3 CY2025 revenue of $70.45 million, surpassing analyst expectations by 61%, but marking a 16.6% decline YoY. The company’s non-GAAP loss per share of $1.25 was 10.5% below estimates. Novavax expects full-year revenue to be around $1.05 billion, in line with analysts’ forecasts. The company specializes in developing protein-based vaccines, with a primary focus on COVID-19 vaccines. While Novavax has shown impressive revenue growth over the past five years, recent performance indicates a slowdown in demand. Analysts project a 32.1% revenue decline in the next 12 months. Market reaction to the earnings report was neutral, with Novavax stock remaining flat at $6.69.

Read more at StockStory Inc.: Novavax (NASDAQ:NVAX) Surprises With Q3 CY2025 Sales